Yet another flare-up over the cost of medicines is playing out in the Netherlands, where the government is angry at Novartis (NVS) for boosting the price of a cancer treatment more than six times — to roughly $26,000 for an infusion — in a convoluted case that has spurred debate about orphan drug status and the ability of local hospitals to make their own lower-cost alternatives.
At issue is a medication called lutetium octreotate that is used to combat neuroendocrine tumors and was originally developed two decades ago by physicians who were affiliated with the Erasmus Medical Center in Rotterdam. Although they formed a company to secure the rights, the hospital became well known for treating patients with the medicine, including former Apple chief executive Steve Jobs.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- Online intelligence briefings
- Frequent opportunities to engage with veteran beat reporters and industry experts
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author
